Novavax | NVAX - Interest Expense On Debt


Novavax reported $5.82M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Adma Biologics USD 1.63M 54K Dec/2025
Agenus USD 16.02M 2.85M Dec/2025
AstraZeneca USD 484M 181M Dec/2025
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
Cassava Sciences USD 129.73M 5.65M Sep/2025
Geron USD 7.3M 1.35M Dec/2025
GlaxoSmithKline GBP 167M 21M Mar/2026
MannKind USD 13.87M 6.54M Dec/2025
Merck USD 479M 67M Mar/2026
Minerva Neurosciences USD 2.31M 60K Jun/2024
Moderna USD 11.49B 36B Mar/2026
Novartis USD 281M 8M Sep/2025
Novavax USD 5.82M 342K Dec/2025
Pfizer USD 711M 59M Dec/2025
Sanofi EUR 178M 203M Mar/2026
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
TG Therapeutics USD 6.53M 187K Dec/2025